Speakers

Jonathan Appleby

Chief Scientific Officer • Cell and Gene Therapy Catapult

Dr Jonathan Appleby is currently Chief Scientific Officer at the UK’s Cell and Gene Therapy Catapult (CGT Catapult).  The CGT Catapult employs over 400 full time staff, spread across four sites.  Dr Appleby leads the London based 1200m2 development laboratories which are focused on the creation of analytical and process development solutions for ATMPs. Prior to joining the CGT Catapult Jonathan was Chief Scientific Officer for cell and gene therapy in GSK’s Rare Diseases Unit where he was accountable for the EU Submission of StrimvelisTM, the first paediatric CD34 Stem Cell Gene Therapy to be licensed anywhere in the world. He was also project leader for a similar asset focused on Metachromatic Leukodystrophy which was licenced to Orchard Therapeutics in 2018 and later approved in Europe.

Jonathan has 20 years’ experience of R&D and has worked in all phases of drug development across a broad range of therapeutic areas.

Also speaking

Uta Griesenbach

Professor of Molecular Medicine, National Heart and Lung Institute • Imperial College London

Amir Hefni

Worldwide Commercial and Region Europe Head for Cell & Gene • Novartis

Owen Smith

Partner • 4Bio

Event Info

Image

2022 Spotlight Roundtables

Take a look at the 2022 sample attendee list for Advanced Therapies Europe here.
Image

Pub & Pints RSVP

Let us know you’re planning on attending.